Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 2/20 | 0.60 |
| ▸ | BRAF | P15056 | 15/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534163 | 0.85 | BTK (0.55) | EPHB4BRAFKDRBTK | |
| SCHEMBL3529709 | 0.85 | BTK (0.59) | EPHB4BRAFCYP3A4KDRBTK | |
| SCHEMBL10259364 | 0.85 | EPHB4 (0.61) | EPHB4BRAFCYP3A4KDRBTK | |
| SCHEMBL3530501 | 0.83 | EPHB4 (0.69) | EPHB4BRAFCYP3A4KDRBTK | |
| SCHEMBL6928473 | 0.82 | EPHB4 (0.58) | EPHB4BRAFCYP3A4KDR | |
| SCHEMBL6924514 | 0.82 | EPHB4 (0.58) | EPHB4BRAFCYP3A4KDRBTK | |
| SCHEMBL5109039 | 0.81 | EPHB4 (0.69) | EPHB4BRAFCYP3A4KDR | |
| SCHEMBL3527128 | 0.80 | CYP2A6 (0.49) | EPHB4BRAFKDRBTK | |
| SCHEMBL3525488 | 0.80 | BTK (0.49) | EPHB4KDRBTK | |
| SCHEMBL5550688 | 0.80 | BRAF (0.49) | EPHB4BRAFKDRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809345-B2 | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-19 | — | — | US | disclosed |
| US-8273736-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2012-09-25 | — | — | US | disclosed |
| US-7737160-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100069371-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
| EP-1648905-B1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20080255184-A1 | Thienopyridine B-Raf Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-10-16 | — | — | US | disclosed |
| US-20080255184-A1 | Thienopyridine B-Raf Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-10-16 | — | — | US | disclosed |
| US-20080255184-A1 | Thienopyridine B-Raf Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-10-16 | — | — | US | disclosed |
| EP-1951728-A2 | THIENOPYRIDINE B-RAF KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBVIE INC. | 2007-07-05 | — | — | US | disclosed |
| WO-2007056625-A2 | THIENOPYRIDINE B-RAF KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056625-A2 | THIENOPYRIDINE B-RAF KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
| US-7202363-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-04-10 | — | — | US | disclosed |
| CN-1856498-A | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LAB (US) | 2006-11-01 | — | — | CN | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
| US-20050020619-A1 | Thienopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020619-A1 | Thienopyridine kinase inhibitors | ABL1, MAP4K2, MAP4K5 | EPHB4 877/4885BRAF 35/4885CYP3A4 2145/4885 |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | EPHB4 896/4885BRAF 26/4885CYP3A4 1935/4885 |
| US-20080255184-A1 | Thienopyridine B-Raf Kinase Inhibitors | BRAF, RAF1, ARAF | EPHB4 651/4885BRAF 1/4885CYP3A4 1249/4885 |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | EPHB4 896/4885BRAF 26/4885CYP3A4 1935/4885 |
| US-20100069371-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | EPHB4 896/4885BRAF 26/4885CYP3A4 1935/4885 |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | EPHB4 896/4885BRAF 26/4885CYP3A4 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.